CIK 1586444
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2017-Q1. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 48.73% | 9 |
| Pharmaceuticals & Biotechnology | 20.50% | 4 |
| Health Care Equipment & Supplies | 16.82% | 4 |
| Life Sciences Tools & Services | 9.43% | 2 |
| Health Care Providers & Services | 4.51% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | TESARO INC. | Unclassified | 6.43% | |
| 2 | CLOVIS ONCOLOGY INC | Unclassified | 6.32% | |
| 3 | INCY | INCYTE CORP | Health Care | 6.18% |
| 4 | IRWD | IRONWOOD PHARMACEUTICALS INC | Health Care | 6.05% |
| 5 | WRIGHT MED GROUP N V | Unclassified | 6.00% | |
| 6 | BMRN | BIOMARIN PHARMACEUTICAL INC | Health Care | 5.84% |
| 7 | PRA HEALTH SCIENCES INC | Unclassified | 5.45% | |
| 8 | EW | Edwards Lifesciences Corp | Health Care | 5.42% |
| 9 | ABIOMED INC | Unclassified | 5.41% | |
| 10 | NEVRO CORP | Unclassified | 5.33% |
11/20 names classified · sector 51.3% of weight · industry 51.3% · mkt cap 46.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 51.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 42% of book weight classified — the grid is NOT representative of the whole book.
Classified: 42.0% of book weight (9/13 names) · unclassified 58.0%: , SNN, BKD, ICLR. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | TESARO INC. | 67,490 | $9M | 6.4% | TRIM −20% |
| 2 | CLOVIS ONCOLOGY INC | 99,101 | $9M | 6.3% | TRIM −34% |
| 3 | INCYINCYTE CORP | 72,051 | $9M | 6.2% | ADD 3% |
| 4 | IRWDIRONWOOD PHARMACEUTICALS INC | 470,000 | $9M | 6.0% | TRIM −30% |
| 5 | WRIGHT MED GROUP N V | 320,420 | $9M | 6.0% | ADD 5% |
| 6 | BMRNBIOMARIN PHARMACEUTICAL INC | 94,454 | $9M | 5.8% | TRIM −10% |
| 7 | PRA HEALTH SCIENCES INC | 106,555 | $8M | 5.4% | TRIM −24% |
| 8 | EWEDWARDS LIFESCIENCES CORP | 67,266 | $8M | 5.4% | TRIM −25% |
| 9 | ABIOMED INC | 55,387 | $8M | 5.4% | TRIM −26% |
| 10 | NEVRO CORP | 105,000 | $8M | 5.3% | ADD 5% |
| 11 | QIAGEN NV | 217,954 | $7M | 5.0% | NEW |
| 12 | SNNSMITH & NEPHEW PLC | 200,000 | $7M | 4.7% | NEW |
| 13 | PORTOLA PHARMACEUTICALS INC. | 120,000 | $7M | 4.6% | NEW |
| 14 | NBIXNEUROCRINE BIOSCIENCES INC | 145,303 | $7M | 4.6% | NEW |
| 15 | BKDBROOKDALE SR LIVING INC | 450,000 | $7M | 4.5% | NEW |
| 16 | ICLRICON PLC | 63,342 | $6M | 4.2% | NEW |
| 17 | VRTXVERTEX PHARMACEUTICALS INC | 46,202 | $6M | 4.1% | TRIM −42% |
| 18 | ALGNALIGN TECHNOLOGY INC | 33,904 | $5M | 3.5% | NEW |
| 19 | ILMNILLUMINA INC | 27,500 | $5M | 3.3% | NEW |
| 20 | ISRGINTUITIVE SURGICAL INC | 5,000 | $5M | 3.2% | NEW |
Where this firm's principals came from and which firms its alumni went on to found.
